SLU-PP-332 news and clinical trials
Also known as: SLU-PP 332 · SLU PP 332 · SLUPP-332 · SLUPP332 · ERR pan-agonist 332 · 4-hydroxy-N'-(naphthalen-2-ylmethylene)benzohydrazide
Updated 31 sources
5 new studies in the last 12 months, newest first: trial registrations and results, PubMed papers, FDA actions and press coverage that name SLU-PP-332. Each line links to the primary source.
April 2026
- StudyPubMed[Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications] (opens PubMed)
A systematic review published in Revista medica de Chile suggests that pharmacological activation of ERRα/β/γ receptors may mimic exercise benefits. Animal models show that synthetic pan-ERR agonists like SLU-PP-332 and SLU-PP-915 improve endurance and metabolic health without evident toxicity.
Revista medica de ChileSystematic reviewPMID 42024694
March 2026
- StudyPubMedChemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling (opens PubMed)
Researchers performed a structure-activity relationship analysis of the exercise mimetic compound SLU-PP-332 to understand how its structure controls its efficacy. Several analogues showed improved metabolic stability and solubility compared to the original compound.
International journal of biological macromoleculesPMID 41850449
February 2026
- StudyPubMedAnalysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes (opens PubMed)
Investigators identified 22 metabolites of the exercise mimetic SLU-PP-332 using human liver fractions. These metabolites were categorized for potential use in doping-control screenings to detect illicit use of the substance in sports.
Drug testing and analysisPMID 41688415
January 2026
- StudyPubMedIn Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential (opens PubMed)
New paper in Rapid communications in mass spectrometry : RCM: In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential.
Rapid communications in mass spectrometry : RCMPMID 41588687
December 2025
- StudyPubMedAn orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity (opens PubMed)
Researchers characterized SLU-PP-915, an orally bioavailable pan-ERR agonist that enhances aerobic exercise performance. The compound increases exercise capacity and induces Ddit4 gene expression similar to previous non-bioavailable agonists.
The Journal of pharmacology and experimental therapeuticsPMID 41421047
Searched as: SLU-PP-332, ERR pan-agonist 332. Summaries are one or two sentences, published only when every number in them appears in the source record. A tracker, not medical advice.